Tango Therapeutics (TNGX) Return on Sales (2020 - 2026)

Tango Therapeutics' Return on Sales history runs 7 years deep, the most recent figure standing at 0.02% for Q1 2026.

• On a quarterly basis, Return on Sales rose 6.0% year-over-year to 0.02% in Q1 2026; TTM through Mar 2026 was 0.02%, a 1.0% increase from a year earlier, with the FY2025 full-year figure at 0.02%, up 1.0% from the prior year.
• Return on Sales slipped to 0.02% in Q1 2026 per TNGX's latest filing, from 0.02% in the prior quarter.
• Across five years, Return on Sales topped out at 0.0% in Q3 2025 and bottomed at 0.12% in Q2 2025.
• The 5-year median for Return on Sales is 0.04% (2022), against an average of 0.04%.
• Biggest YoY gain for Return on Sales was 8 bps in 2025; the steepest drop was 11 bps in 2025.
• Year by year, Return on Sales stood at 0.05% in 2022, then dropped by 25 bps to 0.06% in 2023, then tumbled by 62 bps to 0.09% in 2024, then jumped by 82 bps to 0.02% in 2025, then retreated by 16 bps to 0.02% in 2026.
• Per Business Quant, the three latest TNGX Return on Sales figures stand at 0.02% (Q1 2026), 0.02% (Q4 2025), and 0.0% (Q3 2025).